Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow LSTA by emailGet an email when LSTA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LSTA, unsubscribe in one click. Privacy
📣 What LSTA Says Is Next
fourth quarter of 2027 · “Both studies are expected to report topline data in the fourth quarter of 2027.”
Company press release, Sep 17, 2026 · SEC filing
first quarter of 2027 · “The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the first quarter of 2027, encompassing anticipated data milestones from its ongoing clinical trials.”
Company press release, Jan 21, 2026 · SEC filing
in 2026 · “Enrollment is progressing according to plan and completion is expected in 2026.”
Company press release, Nov 6, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full LSTA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LSTA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.